Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
George M. Milne Jr., a director of Amylyx Pharmaceuticals, Inc. (AMLX), sold 30,000 shares of common stock on October 5, 2026, at a weighted average price of $27.6968 per share. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05 under a Rule 10b5-1 trading plan adopted on April 28, 2026. He held 782,881 shares directly after the sale.
George Milne, a director of Amylyx Pharmaceuticals, Inc., reported a proposed sale of 100,000 common shares, with an aggregate market value of $2,779,000. The approximate sale date is October 5, 2026, and Morgan Stanley Smith Barney LLC is listed as the broker.
The shares listed for sale include 86,757 from a private acquisition from the issuer or an affiliate on August 8, 2016, and 13,243 from previously exercised options dated December 11, 2019.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Medical Officer Camille L. Bedrosian sold a total of 10,028 shares of common stock on September 10, 2026. The transactions were made to cover tax withholding obligations arising from the vesting of performance stock units and were described as automatic and not at her discretion. The sales included 7,947 shares at a weighted average price of $32.21 (with individual trades between $31.76 and $32.68) and 2,081 shares at a weighted average price of $33.09 (with trades between $32.85 and $33.29).
Amylyx Pharmaceuticals, Inc. (AMLX) reported that its Chief Financial Officer, James M. Frates, sold a total of 10,810 shares of common stock on September 10, 2026 in open-market transactions. According to the company’s disclosure, these sales were automatically executed to cover tax withholding obligations arising from the vesting of performance stock units and were not made at the CFO’s discretion.
The filing also notes various trusts for which Mr. Frates serves as trustee hold Amylyx shares, with Mr. Frates disclaiming beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Legal Officer Gina Mazzariello sold a total of 9,536 shares of common stock on September 10, 2026 in open-market transactions. Footnotes state these shares were automatically sold to cover tax withholding obligations upon vesting of performance stock units, and not at her discretion.
Amylyx Pharmaceuticals, Inc. (AMLX) director and Co-Chief Executive Officer Justin B. Klee reported selling a total of 30,464 shares of common stock on September 10, 2026. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of performance stock units, and that these sales were automatic and not at his discretion.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen sold a total of 30,464 shares of common stock on September 10, 2026. The filing states these automatic sales were made solely to cover tax withholding obligations from vesting performance stock units and were not at his discretion, with no Rule 10b5-1 plan reported.
Amylyx Pharmaceuticals, Inc. (AMLX) received a Rule 144 notice for a planned sale of common stock for the account of officer Camille L. Bedrosian. The sale relates to the vesting of performance-based restricted stock units on September 10, 2026, covering 22,807 shares to satisfy tax withholding obligations, with sales described as automatic and not at the officer’s discretion.
Amylyx Pharmaceuticals, Inc. (AMLX) received a notice under Rule 144 relating to a planned sale of common stock for the account of Justin B. Klee. The notice covers 60,039 shares of common stock expected to be sold on September 10, 2026, in connection with vesting of performance-based restricted stock units.
The filing states that these shares are required to be sold to satisfy tax withholding obligations upon vesting and that the sales are automatic and not at the discretion of the reporting person. Morgan Stanley Smith Barney LLC is listed as the broker for the transaction, and the shares are listed on NASDAQ.
Amylyx Pharmaceuticals, Inc. (AMLX) received a Rule 144 notice indicating that James M. Frates intends to sell common stock through Morgan Stanley Smith Barney LLC. The sales are connected to the vesting of performance-based restricted stock units scheduled for September 10, 2026.
The filing states that the shares are being sold to satisfy tax withholding obligations arising from this vesting and that these sales were automatic and not at the discretion of the reporting person.